In a cohort of patients with stage I-III colorectal cancer, guanylin mRNA and peptides were lost and/or significantly lower in cancerous tissues compared to healthy adjacent tissues in >85% of cases23, and targeting the GC-C pathway at the early stages of colorectal cancer has been proposed as a candidate therapeutic strategy24–27. The gene discussed is GUCY2C; the disease is colorectal cancer.